Want to see ITGR full AI Analyst Report?
Top Page
Integer Holdings
(NYSE:ITGR)
Select Model
Select Model
Rating:66Neutral
Price Target:
$131.00
▲(32.83% Upside)
Action:Reiterated
Date:08/01/26
The score is held back primarily by mixed fundamentals (moderate leverage, weaker cash conversion, and recent margin compression) and a downshift in 2026 guidance from the earnings call. These are partly offset by strong technical momentum (price well above all key moving averages). Valuation also tempers upside, with a ~29.9 P/E and no dividend yield provided.
Positive Factors
Market position & pipeline
Integer's diversified exposure across cardiac, vascular, electrophysiology and neuromodulation plus a stated robust pipeline supports multi-year organic growth. Outsourced manufacturing ties to OEM new‑product ramps create durable, contract-driven revenue streams and speak to sustained market relevance.
Negative Factors
Guidance reset & profitability pressure
The downward 2026 guidance and trimmed profitability outlook reflect structural margin sensitivity to demand and mix. Reduced profit guidance implies weaker near‑term cash generation and highlights the firm's exposure to program timing and fixed cost absorption challenges over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Market position & pipeline
Integer's diversified exposure across cardiac, vascular, electrophysiology and neuromodulation plus a stated robust pipeline supports multi-year organic growth. Outsourced manufacturing ties to OEM new‑product ramps create durable, contract-driven revenue streams and speak to sustained market relevance.
Read all positive factors
Integer Holdings Key Performance Indicators (KPIs)
Integer Holdings (ITGR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.42B
Dividend YieldN/A
Average Volume (3M)438.04K
Price to Earnings (P/E)29.9
Beta (1Y)0.49
Revenue Growth5.48%
EPS Growth77.43%
CountryUS
Employees11,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)4.06
Shares Outstanding33,954,838
10 Day Avg. Volume401,228
30 Day Avg. Volume438,042
Financial Highlights & Ratios
PEG Ratio-1.49
Price to Book (P/B)1.56
Price to Sales (P/S)1.48
P/FCF Ratio25.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$108.25Price Target Upside9.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)6.08
Revenue Forecast (FY)$1.82B
Integer Holdings Business Overview & Revenue Model
Company Description
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business int...
How the Company Makes Money
Integer makes money primarily by providing outsourced manufacturing and related services to medical device companies under customer contracts. Key revenue streams include: (1) Contract manufacturing of medical device components and assemblies (e.g...
Integer Holdings Earnings Call Summary
Earnings Call Date:Apr 30, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Neutral
The call conveyed a mixed picture: a modest top-line improvement in Q1 (reported +0.5%, organic +1.3%) and several strategic positives (share buybacks, lower interest expense, targeted cost actions, pipeline strength and a Board-initiated strategic review) were offset by meaningful near-term profitability pressures (adjusted operating income down 14%, margin contraction of 230 bps), weaker cash flow in Q1, and a downward revision to full-year 2026 revenue and profit guidance. Management characterizes the demand softness—primarily in electrophysiology—as temporary normalization and emphasized actions to protect long-term growth, but the guidance cuts and margin contraction represent notable near-term headwinds.Positive Updates
Quarterly Revenue Growth
Q1 2026 sales of $440 million, up 0.5% on a reported basis and up 1.3% on an organic basis versus the prior year.
Negative Updates
Operating Profitability Decline
Adjusted operating income declined 14% year-over-year in Q1 and adjusted operating margin contracted by 230 basis points to 13.9%, driven primarily by lower fixed cost absorption.
Read all updates
Q1-2026 Updates
Positive
Negative
Quarterly Revenue Growth
Q1 2026 sales of $440 million, up 0.5% on a reported basis and up 1.3% on an organic basis versus the prior year.
Read all positive updates
Company Guidance
Integer updated its 2026 guidance with full‑year reported sales now expected at $1.805–$1.835 billion (down 1%–3% YoY) and organic sales flat to down 1% (including a ~3%–4% headwind from three new products; organic growth excluding those products ~3%–4%); inorganic decline ~1% (Portable Medical exit); C&V expected flat to down low‑single digits, CRM&N flat to up low‑single digits, and other markets down ~$34M–$36M. Profitability outlook: adjusted EBITDA $375M–$399M (down 1%–7%), adjusted operating income $285M–$305M (down 5%–11%) with sequential margin improvement expected (Q2 operating margin +80–140 bps and continuing improvement through 2026), adjusted net income $200M–$220M (down 3%–11%) and adjusted EPS $5.83–$6.40 (flat to down 9%). Cash/debt targets: cash flow from operations $185M–$205M (≈$15M lower at midpoint), CapEx $95M–$105M (~5%–6% of sales), free cash flow $85M–$105M, year‑end net total debt $1.185B–$1.205B and leverage expected in the 2.5x–3.5x trailing‑4Q adjusted EBITDA target range (Q1 net total debt $1.264B, leverage 3.2x). Q1 actuals and drivers: sales $440M (+0.5% reported, +1.3% organic), adjusted EBITDA $85M (‑7%), adjusted operating margin 13.9% (‑230 bps), adjusted net income $41M (‑10%), adjusted EPS $1.20 (‑8%), cash from ops $25M, CapEx $24M, free cash flow $1M; interest expense was $4M lower (helping EPS by ~$0.10), and share repurchases of $50M in Q4 ’25 (~700k shares) and $50M in Q1 ’26 (~600k shares) reduced weighted shares ~2% (adding ~$0.02 to EPS).Integer Holdings Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
66
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.85B | 1.85B | 1.72B | 1.56B | 1.33B | 1.22B |
| Gross Profit | 431.27M | 425.81M | 461.18M | 411.52M | 346.65M | 336.97M |
| EBITDA | 332.57M | 293.66M | 332.94M | 275.71M | 221.75M | 224.65M |
| Net Income | 141.80M | 102.76M | 119.90M | 90.65M | 66.38M | 96.81M |
Balance Sheet | ||||||
| Total Assets | 3.41B | 3.41B | 3.08B | 2.94B | 2.79B | 2.58B |
| Cash, Cash Equivalents and Short-Term Investments | 8.12M | 17.16M | 46.54M | 23.67M | 24.27M | 17.89M |
| Total Debt | 1.38B | 1.40B | 1.10B | 1.05B | 1.01B | 905.81M |
| Total Liabilities | 1.71B | 1.66B | 1.46B | 1.42B | 1.38B | 1.23B |
| Stockholders Equity | 1.70B | 1.75B | 1.62B | 1.52B | 1.42B | 1.35B |
Cash Flow | ||||||
| Free Cash Flow | 99.80M | 105.12M | 99.85M | 60.27M | 41.65M | 103.20M |
| Operating Cash Flow | 189.57M | 196.15M | 205.21M | 180.21M | 116.38M | 156.67M |
| Investing Cash Flow | -111.47M | -270.73M | -195.41M | -163.37M | -200.42M | -271.00M |
| Financing Cash Flow | -104.19M | 43.56M | 13.32M | -18.01M | 92.48M | 81.99M |
Integer Holdings Technical Analysis
Positive
98.62
Price Trends
93.80
Positive
90.06
Positive
85.02
Positive
Market Momentum
1.65
Negative
60.76
Neutral
71.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITGR, the sentiment is Positive. The current price of 98.62 is above the 20-day moving average (MA) of 97.46, above the 50-day MA of 93.80, and above the 200-day MA of 85.02, indicating a bullish trend. The MACD of 1.65 indicates Negative momentum. The RSI at 60.76 is Neutral, neither overbought nor oversold. The STOCH value of 71.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ITGR.
Integer Holdings Risk Analysis
Integer Holdings disclosed 40 risk factors in its most recent earnings report. Integer Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Integer Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $1.44B | 11.08 | 17.98% | ― | 8.94% | 102.92% | |
71 Outperform | $4.45B | 40.68 | 9.13% | ― | 12.40% | ― | |
69 Neutral | $2.63B | 15.21 | 41.92% | ― | 30.24% | 244.83% | |
66 Neutral | $3.42B | 29.85 | 8.23% | ― | 5.48% | 77.43% | |
64 Neutral | $9.94B | -51.30 | -27.07% | ― | 41.55% | -96.75% | |
53 Neutral | $1.49B | -11.47 | -443.09% | ― | 22.55% | 27.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ITGR
Integer Holdings
121.21
14.69
13.79%
ATEC
Alphatec Holdings
9.52
-4.25
-30.86%
GKOS
Glaukos
166.72
80.56
93.50%
LIVN
LivaNova
80.14
39.01
94.85%
INSP
Inspire Medical Systems
50.21
-75.89
-60.18%
TMDX
TransMedics Group
76.51
-44.04
-36.53%
Integer Holdings Corporate Events
Business Operations and StrategyExecutive/Board Changes
Integer Holdings Announces Executive Role Transition and Compensation
Neutral
Jun 26, 2026
On June 24, 2026, Integer Holdings’ board-level Compensation and Organization Committee approved changes to the compensation of Jim Stephens in connection with his move from President, Cardiac Rhythm Management Neuromodulation, to Executive...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Integer Holdings Enhances Executive Protections Amid Strategic Review
Positive
May 22, 2026
In connection with its ongoing strategic review to maximize stockholder value, Integer Holdings’ board and Compensation and Organization Committee approved, on May 18 and May 20, 2026, enhanced change-of-control protections and sizable cash ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.